Quantum-Si incorporated operates the first next-generation protein sequencing platform for the healthcare industries.
| Revenue (TTM) | $1.60M |
| Gross Profit (TTM) | 562,000 |
| EBITDA | $-87.36M |
| Operating Margin | -7450.00% |
| Return on Equity | -49.10% |
| Return on Assets | -25.70% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.82 |
| Price-to-Book | 1.40 |
| Price-to-Sales (TTM) | 181.38 |
| EV/Revenue | 89.92 |
| EV/EBITDA | 0.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -41.80% |
| Shares Outstanding | $198.95M |
| Float | $180.22M |
| % Insiders | 10.45% |
| % Institutions | 24.65% |
Volatility is currently contracting
Quantum-Si NASDAQ: QSI reported lower third-quarter revenue and narrowed its net loss as it prepared for the planned second-quarter 2027 commercial launch of its Proteus protein sequencing platform.
Quantum-Si incorporated (QSI) Q3 2026 Earnings Call Transcript
BRANFORD, Conn., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will provide a business update and report financial results for the third quarter 2026 on Thursday, November 5, 2026.
BRANFORD, Conn., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Listing Rule 5450(a)(1).
Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of the S&P 500's annual returns with more positive years than all the other quarters. Small cap healthcare/biotech, technology, and consumer cyclicals—like PRME, CRNC, and FOSL—are highlighted as early breakout candidates with strong institutional interest and analyst targets.
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.
BRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced interim development results comparing its next-generation Proteus™ platform with its commercially available Platinum® Pro instrument.
BRANFORD, Conn., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that it has demonstrated sequencing with detection of 18 amino acids using a developmental kit run on integrated Proteus™ instruments.
BRANFORD, Conn., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced the expansion of a roadshow designed to accelerate market education on its Proteus platform and applications for protein sequencing.
BRANFORD, Conn., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced that it will be participating in the H.C.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QSI and any ticker you trade — then tracks every position and per-strategy win rate.
